March 5th, 2021 | by BTP Admin
On Friday 5th March, Local State MP for Mount Ommaney, MP Jess Pugh, Local Oxley Federal MP Hon Milton Dick, and Shadow Minister Hon Ed Husic, Minister for Industry and Innovation, visited the BTP Westlink Green Precinct to help celebrate BTP tenant, iiSolutions after they successfully received funding from Ignite Ideas, a fund proudly supported by the Advance Queensland initiative.
The Members of Parliament were treated to morning tea, while iiSolutions presented their initiative to the room, that earnt them Tier 1 funding worth $100,000.
The initiative was developed to help Queensland based start-ups and small to medium businesses commercialise innovative products, processes and services and empower them to grow and compete in a global market, creating new jobs in multiple industries.
Mick Joslin, Managing Consultant and Director of iiSolutions says, “We’re very excited and proud to be selected for an Ignite Ideas, Advance Queensland Grant. This grant allows us to commercialise and promote our innovative Outside Plant (OSP) Software which helps Smart Cities and other industries, such as Digital Hospitals, Innovative Universities and Railway Companies, map their external assets and fibre optic networks”.
For iiSolutions, the grant will assist with the legal registration of the software’s intellectual property and the development of marketing initiatives and sales focused activities for the OSP product to domestic and international customers. It will also enable iiSolutions to grow this sector of their business and in turn, create more Queensland jobs.
For more information on iiSolutions please visit https://iisolutions.com.au/outside-plant-osp/.
March 3rd, 2021 | by BTP Admin
Great news for Brisbane Technology Park, with Pepper Kids Therapy opening their doors to our community in April.
Based in 35 Miles Platting Road, the brand-new bespoke facility will provide a range of services to local children.
Pepper Kids Therapy is a multi-discipline team of occupational therapists, speech pathologists and psychologists providing a holistic approach to helping children with a disability. Highly experienced, the team has a particular focus on early childhood early intervention (ECEI) and welcomes all self-managed and plan managed NDIS participants.
They offer the below services:
Our occupational therapists work with children to build independence and fundamental functional skills (e.g. motor skills, social skills), providing much needed help for medical conditions including intellectual disabilities, autism and other developmental disorders, mental illness, physical disabilities, neurological conditions, stroke and injury or burns victims.
Our psychologists can help children who have problems coping with difficulties, particularly those with autism. We help children to deal with anxiety and to improve their coping skills, social skills and behaviour management. We also work with parents to better manage their child’s difficult behaviours
Speech and language skills are essential for learning, understanding and communicating. Challenges with speech and language can make it difficult for children with a disability to communicate effectively. This can affect their ability to reach their potential.
Our speech pathologists can assist with speech, communication, listening, understanding, social skills and a whole lot more.
We offer training workshops and individual coaching programs for dealing with intense behaviours in children using evidence backed programs. At Pepper Kids Therapy we tailor our approach to therapy to benefit not only the child but the parent/caregiver also, providing a holistic approach to helping your child meet their goals.
Please visit pepperkidstherapy.com.au for more information.
March 3rd, 2021 | by BTP Admin
$231.8 million U.S. funding awarded to Ellume COVID-19 Home Test that integrates AnteoBind™ for superior sensitivity
Brisbane, AUS, February 15, 2021 — AnteoTech’s long-term customer Ellume, producer of next-generation digitally enabled diagnostic solutions, has secured a $231.8 million agreement with the U.S. Government to support accelerated manufacture of its COVID-19 home test. The test makes use of AnteoTech’s unique AnteoBind™ technology to support significantly improved sensitivity, and is the first rapid self-test for SARS-CoV-2 detection authorized by the United States Food and Drug Administration (FDA) for use without a prescription. Through the patented AnteoBind technology and the expertise and know-how delivered via its Contract Services in assay development and bioconjugation, AnteoTech continues to address the pressing challenges of the point-of-care diagnostics, biopharmaceutical and vaccine development markets.
With the help of AnteoTech’s AnteoBind technology, the Ellume COVID-19 Home Test provides accurate results in 15 minutes or less, detecting SARS-CoV-2 in both symptomatic and asymptomatic individuals. Ellume’s offering is the first test which utilizes AnteoBind to receive FDA Emergency Use Authorization (EUA).
Pictured: The Ellume COVID-19 Home Test.
“With the Ellume test receiving FDA authorization and subsequent significant financial backing from the U.S. Government, this is further evidence of the immense value the AnteoBind technology continues to bring to the life sciences industry for life-changing solutions,” said Derek Thomson, Chief Executive Officer of AnteoTech. “The capabilities of high-sensitivity diagnostics, such as Ellume’s COVID-19 Home Test, will ultimately enable rapid and reliable screening to minimize community spread, relieve burden on healthcare systems and facilitate the reopening of economies.”
AnteoBind is a nano-sized molecular glue used to facilitate simpler, faster and more reliable bioconjugation. The improved conjugation process increases the performance for diagnostic assays, and enables superior quality control, candidate screening and efficacy-measurement processes in biopharmaceutical and vaccine development. The Ellume COVID-19 Home Test is an example of how AnteoBind technology can aid in delivering conjugation stability, unmatched sensitivity and batch-to-batch reproducibility – all while being manufactured at scale.
Dr. Sean Parsons, Chief Executive Officer of Ellume, said “Our recent Emergency Use Authorization was a key milestone in our mission to make a significant contribution to global health. AnteoTech’s AnteoBind has greatly assisted us in the development of a highly sensitive test that is vital for an effective COVID-19 mitigation strategy. We look forward to our continued partnership with AnteoTech as we deliver accurate diagnostic solutions to the market.”
AnteoTech’s AnteoBind can be purchased directly as an AnteoBind-based ready-to-use kit to streamline and improve the conjugation process, or is available through AnteoTech’s Assay Development Services. The Assay Development Services are focused on the application of AnteoBind, and draw on the AnteoTech team’s extensive biomedical research and assay development experience, particularly in difficult conjugation assay design and quantitative assay design.
For more information on AnteoTech’s AnteoBind technology and Contract Services, please visit: https://www.anteotech.com/life-science/anteobind/.
About AnteoTech Ltd.
AnteoTech is a surface chemistry company with Intellectual Property in its core technology product groups AnteoBindTM, AnteoCoatTM, and AnteoReleaseTM. The company is committed to creating shareholder value by identifying and solving critical global industry problems through unique value-add solutions. AnteoTech serves companies in the life sciences, diagnostics and energy markets.
For more information:
+61 7 3219 0085
Media enquires: Janice Foley
December 3rd, 2020 | by BTP Admin
The Suites by Graystone has the opportunity to work and build relationships with incredible businesses and their teams and working with TeleMedC is no different. We sat down with CEO, Founder and Chair of the Board, Para Segaram to tell us more about TeleMedC as they are paving the way for accessible retinal imaging with Artificial Intelligence software.
What is TeleMedC currently working on?
We are currently working on portable, retinal image grading technologies that will be delivered at low-cost to pharmacies, community clinics and primary care providers in the world market. This technology automates and speeds up the diagnosis and detection of many chronic eye diseases including Diabetic Retinopathy and Glaucoma.
What Is Diabetic Retinopathy?
Diabetes affects over 1.7 million Australians and one third show signs of Diabetic Retinopathy. Diabetic Retinopathy is a condition where blood vessels in the back of the eye begin to bleed. As the condition worsens the leakage damages the patient’s eyesight. For diabetics, it is the world’s leading cause of vision loss or even blindness.
How does the device work?
Our portable scanning device, the EyeScan R2 is a fundus imaging camera, a non-invasive device that takes photos of the back of the eye. Due to its relative small size and low price in comparison to much larger, more expensive cameras that can only be found at eye specialists’ clinics and/or hospitals, it allows Family/GP clinics, pharmacies, etc. to have an easy to use camera to screen Diabetic Retinopathy and other eye diseases in a fast, efficient and very accurate way. Our AI Diabetic software has been TGA certified in Australia, CE marked in Europe and HSA certified in Singapore.
How will this technology help in future?
Our screening/grading system will greatly help vast numbers of people to be screened whom, otherwise would not check their eyes. It is/will be extremely useful in the prevention of Diabetic Retinopathy, a precursor of Diabetes. These eye screenings are very accurate (97%), very fast (within 2 minutes) and very affordable.
Our combined system of the EyeScan2 + our integrated AI technology can be placed in any family clinic or pharmacy where people can be screened without the need to go to an eye specialist. It is the first step towards a predictive and preventive eye care. It is significantly less expensive and less time consuming than a visit to an eye doctor: it is fast, reliable and affordable.
Our system not only detects the disease as it grades the disease as mild, moderate or severe alerting the patient to see an eye specialist if necessary. A referral can be given at the time if performed during a GP visit. This allows patients to be screened as part of an overall health check and work with the GP in the best way to manage the disease. Further to this, by making screenings affordable and available in many locations allows a vast number of people, who would not otherwise be screened. It decreases the overall burden on hospitals allowing the eye specialists/surgeons to focus on the most needed cases and eye surgeries, reducing the overall costs of healthcare.
Having our system in place as a basic tool in predicting and preventing eye disease allows large populations to have access to affordable and easy eye screenings that if not timely detected can lead to unnecessary blindness.
For more information on TeleMedC please visit https://www.telemedc.com/.
December 3rd, 2020 | by BTP Admin
The Graystone construction team have returned to BTP Northshore to deliver the fifth commercial office building at the precinct.
Once complete, 385 Macarthur Avenue will provide more than 3,500 square metres of lettable area across three levels and target a 5 star NABERS energy rating.
Designed by renowned Brisbane architect BlightRayner, whose team are behind some of Brisbane’s most iconic projects including the Goodwill and Kurilpa bridges, flood resistant ferry terminals and the Brisbane Magistrates Court, 385 Macarthur Avenue is set to raise the bar for contemporary suburban office design.
The property will feature high quality internal finishes and include a luscious green ‘third space’ outside the building to deliver additional shaded informal meeting and recreation areas. Located on the doorstep of the recently completed Kingsford Smith Drive bikeway, resident tenants will benefit from premium end of trip facilities and bicycle storage.
Interest in the project has elevated with increased demand from traditionally CBD occupiers looking to relocate to more “COVID-safe” buildings with higher car parking availability in the suburbs. Spaces are filling fast, with tenancies still available from 200-2,000 square metres and available from July 2021.